Non‑invasive imaging of Toll‑like receptor 5 expression using 131I‑labeled mAb in the mice bearing H22 tumors

Yang,Changya; Yun,Qingying; Sun,Hukui; Yang,Guangjie; Liang,Ting; Zhang,Chao; Song,Jing; Han,Jiankui; Hou,Guihua

doi:10.3892/ol.2014.2025

Non‑invasive imaging of Toll‑like receptor 5 expression using 131I‑labeled mAb in the mice bearing H22 tumors

Authors:
- Changya Yang
- Qingying Yun
- Hukui Sun
- Guangjie Yang
- Ting Liang
- Chao Zhang
- Jing Song
- Jiankui Han
- Guihua Hou
View Affiliations

Affiliations: Key Laboratory for Experimental Teratology of the Ministry of Education and Institute of Experimental Nuclear Medicine, School of Medicine, Shandong Univeristy, Jinan, Shandong 250012, P.R. China, Department of Laboratory, The Second Affiliated Hospital, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250012, P.R. China, Department of Nuclear Medicine, Qilu Hospital, School of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Nuclear Medicine, Qilu Hospital, School of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: April 2, 2014 https://doi.org/10.3892/ol.2014.2025
Pages: 1919-1924

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Toll‑like receptor 5 (TLR5) is overexpressed in several cancers and metastases, and presents an enticing target for molecular imaging of primary tumors. In the present study, 131I‑anti‑TLR5 monoclonal antibody (mAb) was evaluated for its use as a novel radiotracer for imaging hepatocarcinoma in mice bearing H22 tumors. The expression of TLR5 was analyzed by quantitative polymerase chain reaction and immunohistochemistry. The anti‑TLR5 mAb and isotype immunoglobulin G (IgG) were radiolabeled with iodine‑131 by the Iodogen method. The in vitro stability of iodinalized probes was determined in serum or saline for a series of times, and then evaluated with radio‑thin‑layer chromatography. The biodistribution study and autoradiography were performed in H22 tumor‑bearing mice. It was found that H22‑xenografted tumor tissue exhibited a higher level of TLR5 expression compared with normal liver tissues. 131I‑anti‑TLR5 mAb and 131I‑IgG were obtained subsequent to purification, with high radiochemical purity (>95%), and remained stable for 48 h in human serum. The target‑to‑non‑target ratio in the 131I‑anti‑TLR5 mAb group was significantly higher compared with the 131I‑IgG group. The biodistribution study and autoradiography demonstrated that 131I‑anti‑TLR5 mAb was specifically retained in hepatocarcinoma with a high tumor uptake. Altogether, these results show that 131I‑anti‑TLR5 mAb is capable of detecting lesions in a TLR5‑expressing tumor, with high target selectivity, and may offer a promising agent for hepatocarcinoma diagnosis and encourage further investigation.

View Figures

View References

1	Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 15:5–13. 2010. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
3	Bruix J and Sherman M; the American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kutikhin AG: Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol. 72:1095–1116. 2011. View Article : Google Scholar : PubMed/NCBI
5	Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, et al: Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol. 176:7021–7027. 2006. View Article : Google Scholar
6	Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al: Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 11:1173–1179. 2005. View Article : Google Scholar : PubMed/NCBI
7	Cook DN, Pisetsky DS and Schwartz DA: Toll-like receptors in the pathogenesis of human disease. Nat Immunol. 5:975–979. 2004. View Article : Google Scholar : PubMed/NCBI
8	Killeen SD, Wang JH, Andrews EJ and Redmond HP: Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer. 95:247–252. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66:3859–3868. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kluwe J, Mencin A and Schwabe RF: Toll-like receptors, wound healing, and carcinogenesis. J Mol Med (Berl). 87:125–138. 2009. View Article : Google Scholar : PubMed/NCBI
11	Cai Z, Sanchez A, Shi Z, Zhang T, Liu M and Zhang D: Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 71:2466–2475. 2011. View Article : Google Scholar : PubMed/NCBI
12	Rhee SH, Im E and Pothoulakis C: Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology. 135:518–528. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sfondrini L, Rossini A, Besusso D, Merlo A, Tagliabue E, Mènard S and Balsari A: Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol. 176:6624–6630. 2006. View Article : Google Scholar : PubMed/NCBI
14	Kawai T and Akira S: TLR signaling. Cell Death Differ. 13:816–825. 2006. View Article : Google Scholar : PubMed/NCBI
15	Eiró N, Altadill A, Juárez LM, et al: Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatol Res. Jun 6–2013.(Epub ahead of print). View Article : Google Scholar
16	Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS, et al: Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci USA. 110:E1857–E1866. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhu K, Dai Z and Zhou J: Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 1:102013. View Article : Google Scholar : PubMed/NCBI
18	Pant V, Sen IB and Soin AS: Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun. 34:749–757. 2013.
19	DeNardo DG, Johansson M and Coussens LM: Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 27:11–18. 2008. View Article : Google Scholar : PubMed/NCBI
20	Song EJ, Kang MJ, Kim YS, Kim SM, Lee SE, Kim CH, et al: Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med. 28:115–119. 2011.PubMed/NCBI
21	Rakoff-Nahoum S and Medzhitov R: Toll-like receptors and cancer. Nat Rev Cancer. 9:57–63. 2009. View Article : Google Scholar
22	Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al: Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65:5009–5014. 2005. View Article : Google Scholar : PubMed/NCBI
23	Szczepanski MJ, Czystowska M, Szajnik M, et al: Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 69:3105–3113. 2009. View Article : Google Scholar : PubMed/NCBI
24	Chiron D, Pellat-Deceunynck C, Maillasson M, Bataille R and Jego G: Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J Immunol. 183:4371–4377. 2009. View Article : Google Scholar : PubMed/NCBI
25	Salaun B, Coste I, Rissoan MC, Lebecque SJ and Renno T: TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 176:4894–4901. 2006. View Article : Google Scholar : PubMed/NCBI
26	Kauppila JH, Mattila AE, Karttunen TJ and Salo T: Toll-like receptor 5 and the emerging role of bacteria in carcinogenesis. Oncoimmunology. 2:e236202013. View Article : Google Scholar : PubMed/NCBI
27	Park JH, Yoon HE, Kim DJ, Kim SA, Ahn SG and Yoon JH: Toll-like receptor 5 activation promotes migration and invasion of salivary gland adenocarcinoma. J Oral Pathol Med. 40:187–193. 2011. View Article : Google Scholar : PubMed/NCBI
28	Kauppila JH, Mattila AE, Karttunen TJ and Salo T: Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer. 108:638–643. 2013. View Article : Google Scholar : PubMed/NCBI
29	Cai Z, Sanchez A, Shi Z, Zhang T, Liu M and Zhang D: Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 71:2466–2475. 2011. View Article : Google Scholar : PubMed/NCBI